ULSCs is under clinical development by RESTEM and currently in Phase I for Polymyositis. According to GlobalData, Phase I drugs for Polymyositis does not have sufficient historical data to build an ...

However, its usefulness in evaluating muscle lesions in polymyositis and dermatomyositis syndromes (PM/DM) has not been established. Methods 33 patients with PM/DM who had undergone FDG PET were ...

The CDC’s primary medical journal for disseminating public health information went unpublished this week — seemingly for the first time ever — amid a communications freeze issued by HHS to ...

Current treatments for dermatomyositis include various immunosuppressants and immunosuppressive agents, including ...

The next phase of pre-exposure prophylaxis against SARS-CoV-2 currently rests on the shoulders of a single monoclonal antibody product — but it may not be enough for immunocompromised populations.

Other rheumatological diseases that can increase cancer risk include polymyositis and dermatomyositis. Polymyositis is indicated by progressive weakening of the proximal limb muscles. Conversely ...

Interstitial Lung Disease Center, Division of Pulmonary Sciences and Critical Care Medicine, National Jewish Medical and Research Center and University of Colorado Health Sciences Center, Denver, ...

manchester.ac.uk Objectives: There is a known association between myositis and cancer. The risk is greater in dermatomyositis (DM) than polymyositis (PM), although reliable methods to predict cancer ...

Special Olympian Chelsea Frederick will be remembered for many remarkable achievements, including winning a medal on the world stage.

MIAMI, Jan. 10, 2025 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today ...